Anwer M S, Kroker R, Hegner D
Naunyn Schmiedebergs Arch Pharmacol. 1978 Mar;302(1):19-24. doi: 10.1007/BF00586591.
The effect of rifamycin SV and rifampicin on hepatic acid uptake was studied using isolated rat hepatocytes in presence and in absence of albumin. The drugs inhibited cholate uptake more than taurocholate uptake and the inhibition was of non-competitive type. In presence of 3% albumin the inhibitory effect of the drugs was more for cholate and less for taurocholate uptake than in absence of albumin. Neither the binding of bile acids nor that of the drugs to albumin was altered by one another. Thus the effect in presence of albumin cannot be explained by the binding of the drugs and bile acids to albumin alone. It is suggested that albumin interacts with hepatic bile acid uptake process and this interaction with cholate uptake is different from that with taurocholate uptake. This additional and different effect of albumin may explain the effect of the drugs in presence of albumin. The results may be of clinical significance in rifamycins treatments.
在有和没有白蛋白存在的情况下,使用分离的大鼠肝细胞研究了利福霉素SV和利福平对肝脏酸摄取的影响。这些药物对胆酸盐摄取的抑制作用比对牛磺胆酸盐摄取的抑制作用更强,且这种抑制作用属于非竞争性类型。与没有白蛋白时相比,在存在3%白蛋白的情况下,药物对胆酸盐摄取的抑制作用更强,而对牛磺胆酸盐摄取的抑制作用较弱。胆汁酸与药物和白蛋白之间的结合彼此均未改变。因此,在有白蛋白存在时的效应不能仅通过药物和胆汁酸与白蛋白的结合来解释。提示白蛋白与肝脏胆汁酸摄取过程相互作用,且这种与胆酸盐摄取的相互作用不同于与牛磺胆酸盐摄取的相互作用。白蛋白的这种额外且不同的效应可能解释了在有白蛋白存在时药物的效应。这些结果可能在利福霉素治疗中具有临床意义。